Company Encyclopedia
View More
name
Cellectis
CLLS.US
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
1.946 T
CLLS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking121/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-30.75%E
    • Profit Margin-42.83%E
    • Gross Margin100.00%A
  • Growth ScoreB
    • Revenue YoY129.04%A
    • Net Profit YoY58.15%B
    • Total Assets YoY-13.35%E
    • Net Assets YoY-22.37%E
  • Cash ScoreB
    • Cash Flow Margin-233.50%D
    • OCF YoY129.04%A
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreD
    • Gearing Ratio70.71%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    07:30 ET Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications

    Moligo Technologies and Cellectis have published a study in Nature Communications demonstrating the potential of enzymatically synthesized single-stranded DNA (ssDNA) for non-viral gene editing. This method shows high efficiency in gene insertion in hematopoietic stem cells, offering a scalable alternative to viral vectors. The study highlights the advantages of circular ssDNA over linear formats and marks a significant advancement in developing next-generation cell and gene therapies.

    prnewswire·
    US
    CLLS
    +3.65%
    prnewswire·
    US
    CLLS
    +3.65%

    Why Cellectis Stock Is Trading Higher Today

    Cellectis A/S announced a breakthrough in gene therapy using circular single-stranded DNA (CssDNA) for efficient gene insertion in hematopoietic stem and progenitor cells (HSPCs). This advancement, utilizing TALEN technology, enhances non-viral gene therapy potential. CssDNA showed higher efficiency and applicability across cell types, marking a pivotal step in cell and gene therapies. Consequently, Cellectis' stock rose by 8.27% to $4.45. The company has $225 million in cash reserves, sufficient to fund operations until the second half of 2027.

    fidelity·
    US
    CLLS
    +3.65%
    fidelity·
    US
    CLLS
    +3.65%

    Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

    NEW YORK, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Cellectis ( the "Company" ) ( Euronext Growth: ALCLS - NASDAQ: CLLS ) , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes an article in Nature ...

    GlobeNewswire·
    US
    CLLS
    +3.65%
    GlobeNewswire·
    US
    CLLS
    +3.65%

    Cellectis Achieves Breakthrough Non-Viral Gene Insertion in Stem Cells

    Cellectis SA has achieved a breakthrough in non-viral gene editing for hematopoietic stem and progenitor cells (HSPCs) using circular single-stranded DNA (CssDNA). This method demonstrated 3-5 times higher knock-in efficiency than linear single-stranded DNA (LssDNA), with rates exceeding 40%. CssDNA also enabled gene insertion at multiple loci and showed better engraftment and gene edit retention in murine models compared to viral vectors. The research is published in Nature Communications.

    Reuters·
    US
    CLLS
    +3.65%
    Reuters·
    US
    CLLS
    +3.65%

    Wells Fargo Keeps Their Hold Rating on Cellectis SA (CLLS)

    Wells Fargo analyst Nick Abbott maintained a Hold rating on Cellectis SA with a $4.00 price target. Abbott has an average return of -43.6% and an 11.76% success rate. Cellectis SA also received a Hold from JonesTrading's Soumit Roy, while Barclays maintained a Buy rating on November 10.

    Tip Ranks·
    US
    CLLS
    +3.65%
    Tip Ranks·
    US
    CLLS
    +3.65%
    © 2025 Longbridge｜Disclaimer